PATENT COOPERATION TREATY

PCT

TRANSLATION INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 25974 WO		FOR FURTHER	FOR FURTHER ACTION See Form PCT/IPEA/4			
International application No.		International filing d	•			
PCT	/EP2004/01387	9 07.12.200	04	10.12.2003		
Internati	ional Patent Classification (II	PC) or national classification and	l IPC	•		
C12	Q1/70, G01 N3	33/53				
Applicant GREINER BIO-ONE GMBH						
1.	_	onal preliminary examination renitted to the applicant according	-	by this International Preliminary Examining Authority		
2.	This REPORT consists of a total of 8		sheets, including this cover sheet.			
3.	This report is also accompa	nnied by ANNEXES, comprising	;:			
	a. (sent to the app	licant and to the International B	ureau) a total of _	sheets, as follows:		
		ntaining rectifications authorized	_	rings which have been amended and are the basis for this report and/or this Authority (see Rule 70.16 and Section 607 of the Administrative		
	sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental			·		
	Box.					
	b (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s))			number of electronic carrier(s))		
	, containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see			, containing a sequence listing and/or tables		
		e Administrative Instructions).	as indicated in the	supplemental box Relating to sequence Listing (see		
4.	This report contains indicat	tions relating to the following ite	ems:			
	Box No. I B	easis of the report				
	Box No. II P	riority				
	Box No. III N	on-establishment of opinion wit	h regard to novelty	y, inventive step and industrial applicability		
	Box No. IV L	ack of unity of invention				
	BON 110.	easoned statement under Article itations and explanations support	• •	to novelty, inventive step or industrial applicability;		
	Box No. VI	Certain documents cited				
	Box No. VII C	ertain defects in the internationa	l application			
	Box No. VIII C	ertain observations on the intern	ational application	1		
Date of submission of the demand		Date of completion of this report				
Name and mailing address of the IPEA/EP			Authorized officer			
Facsimile No.			Telephone No.			

Box	No. I		Basis of the report		
1.		_	o the language, this report is based on the international ler this item.	onal application in the language in	which it was filed, unless otherwise
	This report is based on translations from the original language into the following language which is the language of a translation furnished for the purposes of:				
		in	nternational search (Rule 12.3 and 23.1(b))		
		p	ublication of the international application (Rule 12.4	4)	
		ir.	nternational preliminary examination (Rule 55.2 and	/or 55.3)	
2.	With regard to the elements of the international application, this report is based on (replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report):				
		the inte	rnational application as originally filed/furnished		
		the desc	cription:		
		pages	1-58,61-73		as originally filed/furnished 30.09.2005 with letter
		pages*	_59,60	received by this Authority on	of 20.09.2005
		pages*		received by this Authority on	
	\boxtimes	the clai	ms:		
		nos.			as originally filed/furnished
		nos.*		as amended (togethe	er with any statement) under Article 19
		nos.*	1-57	_ received by this Authority on	30.09.2005 with letter of 20.09.2005
		nos.*		received by this Authority on	
	\boxtimes	the dray	wings:	_	
		sheets	1/5-5/5		as originally filed/furnished
		sheets*		received by this Authority on	as originary modifications
		sheets*		_	
	\square				
		a seque	nce listing and/or any related table(s) – see Supplem	nental Box Relating to Sequence L	isting.
3.		The am	endments have resulted in the cancellation of:		
		L th	ne description, pages		
		L th	ne claims, nos.		
		L th	ne drawings, sheets/figs		
		L th	ne sequence listing (specify):		
		aı	ny table(s) related to sequence listing (specify):		
4.		-	port has been established as if (some of) the amend ve been considered to go beyond the disclosure as fi		
		Ll th	ne description, pages		
			ne claims, nos.		
			ne drawings, sheets/figs		
			ne sequence listing (specify):		
	any table(s) related to sequence listing (specify):				
*	If ite		lies, some or all of those sheets may be marked "sup		

Box No. II	II Non-establishment of opinion with regard to novelty, inventive	step and industrial applicability		
The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:				
the entire international application $29-45$ and $53-57$ insofar as they relate to SEQ ID Nos. $8-18$, $20-31$, 42 , 43 , claims Nos. $45-47$ and $83-116$				
becaus	se:			
	the said international application, or the said claims Nos. relate to the following subject matter which does not require an international	al preliminary examination (specify):		
	the description, claims or drawings (indicate particular elements below) or are so unclear that no meaningful opinion could be formed (specify):	said claims Nos.		
	the claims, or said claims Nos. by the description that no meaningful opinion could be formed.	are so inadequately supported		
\boxtimes	no international search report has been established for said claims Nos. 2	9-45 and 53-57		
	the nucleotide and/or amino acid sequence listing does not comply with th Instructions in that:	e standard provided for in Annex C of the Administrative		
	the written form has not been furnished	J J		
	the computer readable form has not been furnished			
	does not comply with the state the tables related to the nucleotide and/or amino acid sequence listing, if			
	technical requirements provided for in Annex C-bis of the Administrative I See Supplemental Box for further details.	nstructions.		

Box	x No. IV Lack of unity of invention	
1.	In response to the invitation to restrict or pay additional fees the applicant has:	
	restricted the claims.	
	paid additional fees.	
	paid additional fees under protest.	
	neither restricted the claims nor paid additional fees.	
2.	This Authority found that the requirement of unity of invention is not complied with and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.	9
3.	This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is:	
	complied with.	
	not complied with for the following reasons:	
	See Supplemental Box.	
4.	Consequently, this report has been established in respect of the following parts of the international application:	
	all parts.	
	29-45 and 53-57 insofar as they relate to SEQ ID Nos. 19, 32, the parts relating to claims Nos. 41, 44, 48, 82 and 117-135	

Вох	Reasoned statement citations and expla				e step or industrial applicabili	ty;
1.	Statement					
	Novelty (N)	Claims	29-45,	53-57		YES
		Claims				NO
	Inventive step (IS)		29-45,	53-57		YES
		Claims				NO NO
	Industrial applicability (IA)	Claims	29-45,	53-57		YES
		Claims				NO
2.	Citations and explanations (Rule	70.7)				
	See Supplementa	l Box	•			

International application No.

PCT/EP2004/013879

Supplemental Box Relating to Sequence Listing			
Continuation of Box No. I, item 2:			
With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this report was established on the basis of:			
a. type of material a sequence listing table(s) related to the sequence listing b. format of material in written format in computer readable form c. time of filing/furnishing contained in the international application as filed filed together with the international application in computer readable form furnished subsequently to this Authority for the purposes of search and/or examination received by this Authority as an amendment* on			
2. In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.			
3. Additional comments:			
The sequence listing in the description, pages 1-20, as			
originally filed.			
* If item 4 in Box No. I applies, the listing and/or table(s) related thereto, which form part of the basis of the report, may be marked "superseded."			

Supplemental Box

In case the space in any of the preceding boxes is not sufficient. Continuation of: Boxes III, IV and V

- 1. The application relates to primers and probes for detecting HPV genotypes.
- 2. Box IV Lack of unity of invention (PCT Rule 13)

Various primers and primer combinations for detecting papilloma viruses are known from the cited prior art. The present application also describes various primers; for those with SEQ ID Nos. 1 to 6 the consensus sequence according to claim 1 can be regarded as a compulsory structural feature (PCT Rule 13.2). SEQ ID No. 7 can be regarded as related because a pair of primers is needed in order to carry out the diagnostic method.

The sequences with SEQ ID Nos. 19, 32, 41, 44, 48, 84 and 117 to 135 are not structurally related to the aforementioned sequences. It is already known that the E1 region is preserved and is therefore suitable for HPV diagnosis, and therefore any inventions based on these SEQ IDs are separate inventions (PCT Rule 13). Since no search fees have been paid for these 25 additional inventions, no comment can be made on them. The applicant has identified another invention in the claims, namely "arrays containing probes from the E1 region" (see the original claims 40 to 56) and has paid an additional fee for this. With the Demand for an International Preliminary Examination the applicant submitted a new set of claims and a letter asking for the International Preliminary Examination to be carried

Supplemental Box

out in respect of the subject matter of the new claims 29 to 45 and 53 to 57 (arrays).

3. Box III - Non-establishment of opinion

Since a search has been carried out only for arrays as specified in the original claims (i.e. containing at least one of sequences 19, 32, 41, 44, 48, 82 and 117 to 135), the following opinion relates only to these arrays.

5. Box V - Novelty (PCT Article 33(2)) and inventive step (PCT Article 33(3))

Arrays containing at least one of sequences 19, 32, 41, 44, 48, 82 and 117 to 135 or having one of these sequences with a maximum of three substitutions are not known from the prior art.

Although claims 1 to 23 are not covered by the present report, it is noted that the primers which they describe are novel over the prior art (DE 100 09 143) and have certain advantages (see Examples 1 to 3). The amplification products obtained using these primers can hybridise onto sequences 19, 32, 41, 44, 48, 82 and 117 to 135. The technical problem addressed is that of providing probes for diagnosing HPV infections. Since the region amplified by the aforementioned primers has advantages in comparison with the prior art, the arrays containing the specified probes can be considered inventive.